

Toward Global Identification of Medicinal Products (IDMP) Implementation: A Focus on Biologics

Ron Fitzmartin, PhD, MBA

Sr. Informatics Advisor
Office of the Director
Center for Biologics Evaluation and
Research (CBER) | FDA

Ta-Jen Chen

Sr. Project Management Officer
Office of Strategic Programs (OSP)
Center for Drug Evaluation and
Research (CDER) | FDA

Vada Perkins, MSc, MS

Executive Director, Regulatory Policy & Innovation
Bayer Pharmaceuticals

- EFPIA ERAO Working Group
- PhRMA IT Working Group
- ISO TC 215 WG 6 IDMP Co-chair
- ICH M2 EFPIA Topic Lead

CDER Small Business & Industry Assistance (SBIA)

January 27, 2022


Topics



ISO IDMP Standards




Challenges to Global IDMP Implementation



Cross-Region Collaboration on Global IDMP Implementation



Solutions for Global IDMP Implementation



IDMP Use Cases for Drugs and Biologics


Topics



ISO IDMP Standards




Challenges to Global IDMP Implementation



Cross-Region Collaboration on Global IDMP Implementation



Solutions for Global IDMP Implementation



IDMP Use Cases for Drugs and Biologics


What is IDMP

The Identification of Medicinal Product (IDMP) is a suite of five ISO standards that:

- Data elements and structure to **uniquely** and **unambiguously** identify medicinal product, Pharmaceutical Product, and substance
 - **common vocabularies** for improved people communication
 - **common message standards** for improved IT system communication
-
- ❖ ISO 11615 – Medicinal Product Identification
 - ❖ ISO 11616 – Pharmaceutical Product Identification
 - ❖ ISO 11238 – Substance Identification
 - ❖ ISO 11239 – Pharmaceutical dose forms, units of presentation and routes of administration
 - ❖ ISO 11240 – Units of measurement



Key Benefits of IDMP




Cross-regions or global agreement on common substance ID and dose form is needed to maximize the benefits

Closer Look at PhPID

PhPID Set

- ❖ PhPID_Substance Level_ **L1** → Substance(s) Term
- ❖ PhPID_Substance Level_ **L2** → Substance Term(s) +Strength+ reference strength
- ❖ PhPID_Substance Level_ **L3** → Substance Term(s) + *Administrable Dose Form*
- ❖ PhPID_Substance Level_ **L4** → Substance(s) Term+ Strength + reference strength + *Administrable Dose Form*

Connecting Medicinal Products - Biologics



Baxter



250 IU



Topics



Challenges with ISO Standard for Global PhPID

- PhPID Set

- ❖ PhPID_Substance Level_**L1** → Substance(s) Term
- ❖ PhPID_Substance Level_**L2** → Substance Term(s) +Strength+ reference strength
- ❖ PhPID_Substance Level_**L3** → Substance Term(s) + *Administrable Dose Form*
- ❖ PhPID_Substance Level_**L4** → Substance(s) Term+ Strength + reference strength + *Administrable Dose Form*


- No global agreement on common substance IDs for Global PhPIDs at all levels
- No global consensus on Dose Form Representations for level 3 and level 4 Global PhPIDs
- Dose Form expression variations among regions
- Strength (and units) expression variations among regions

Challenges discovered and relation to ISO Standards for **substances** (ISO 11238 / TS 19844)

- **Issues:**

1. Global Substance ID has not been identified by regulatory agencies
2. Consistent identification of substance will require global maintenance
3. Can a core set of data fields with non-confidential unambiguously identify a substance?
4. Harmonized capture of standardized information not always well defined for global Substance and PhPID

mRNA vaccine



Comirnaty
Pfizer BioNTech COVID-19 vaccine

TOZINAMERAN

NUCLEIC ACID



Names: TOZINAMERAN ✓
RNA INGREDIENT BNT-162B2
BNT162B2
BNT-162B2

Codes: FDA UNII: 5085ZFP6SJ
CAS: [2417899-77-3](#)
INN: [11889](#)
NCL_THESAURUS: [C173055](#)

Relationships: 5
Subunits: 1

Substance Hierarchy

▼ **TOZINAMERAN**

[TOZINAMERAN LIPID NANOPARTICLE](#)

Issues discovered and relation to ISO Standards for substances (ISO 11238 / TS 19844)

- **Actions**

1. Recommend that UMC be established and recognized as the IDMP maintenance organization (IMO) for substance identifiers
2. Identify the process to establish UMC as the IMO
3. Conduct a pilot for global substance ID
4. ISO TC 215 WG6 to ensure framework for capturing of standardized information including signature field

mRNA vaccine



Comirnaty
Pfizer BioNTech
COVID-19 vaccine

TOZINAMERAN

NUCLEIC ACID



Names: TOZINAMERAN ✓
RNA INGREDIENT BNT-162B2
BNT162B2
BNT-162B2

Codes: FDA UNII: 5085ZFP6SJ

CAS: [2417899-77-3](#)

INN: [11889](#)

NCL_THESAURUS: [C173055](#)

Relationships: 5

Subunits: 1

Substance Hierarchy

▼ [TOZINAMERAN](#)

[TOZINAMERAN LIPID NANOPARTICLE](#)

Challenges discovered and relation to ISO Standards for **dose form** (ISO 11239 / TS 20440)

- **Issues**


1. No cross-region/global agreement on common dosage form
2. Mapping regional dosage form terms is not viable

- **Solution:**

1. To use a centrally maintained set of dose form characteristics for use in global IDMP and generation of PhPID.
2. A pilot project with FDA and UMC was conducted in 2020 / 2021 that demonstrated that dose form characteristics (and codes) is viable solution for global IDMP.

- **Actions**

1. Based on the Pilot project findings, as well as UNICOM findings, ISO TC 215 WG6 has revised the standard documents (in draft).
2. Conduct an additional pilot for dose form characteristic mappings



Challenges Discovered with Dose Form and Strength

❖ Dose Form expression variations

❖ Pfizer Covid-19 vaccine

- EMA – ***Dispersion*** for Injection
- FDA – ***Suspension*** for Injection
- UK – ***Solution*** for Injection*



❖ Strength expression variations – different units

- %, IU, mg/g or mg/mL


❖ AstraZeneca Covid-19 vaccine

- EMA – 2.5×10^8 ***infectious units***
- UK – 5×10^{10} ***viral particles***
- Australia – 5×10^{10} ***viral particles***



* As of 2021

Challenges discovered and relation to ISO Standards for Pharmaceutical product ID (ISO 11616/ TS 20451)



- **Solution:**

- Global dose form ID and Substance ID need to be identified and agreed to by regulatory bodies.
- Propose to include PhPID business rules in a new ISO Technical Report

- **Actions**

- Recommend that WHO-UMC be established and recognized as the IDMP maintenance organization (IMO) for global PhPIDs
- ISO TC215 WG6 to update standard to issues such as use of different units in different regions


Challenges for Global Implementation and Use

- FDA supports and promotes the implementation of the ISO IDMP standards.
- When outstanding challenges with the ISO IDMP standards are resolved and processes for use established, IDMP will be enabled for global use.

Topics



EMA-FDA Collaboration Framework Charter




 EUROPEAN MEDICINES AGENCY
SCIENCE · MEDICINES · HEALTH


 U.S. FOOD & DRUG
 ADMINISTRATION

EMA-FDA Identification of Medicinal Products Collaboration Framework

Charter

Purpose

This charter establishes the EMA – FDA Identification of Medicinal Products (IDMP) Collaboration Framework (Framework) and sets its background, scope and membership, as well as procedures.

The mission of the European Medicines Agency (EMA) is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of human and animal health in the European Union (EU). In the context of International Standards Organisation (ISO) IDMP implementation through SPOR data management services and EU Telematics projects, EMA is responsible for implementing the EU Telematics strategy, leading internationally, or coordinating and supporting interactions between over fifty national competent authorities for both human and veterinary medicines.

The mission of the US Food and Drug Administration (FDA) is to protect the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices, as well, the safety of the nation's food supply, cosmetics, and products that emit radiation. As FDA focuses on the challenges of the global supply chain and foreign sourcing of medicinal products, FDA continues to participate in the development of and to promote the adoption of international harmonized IDMP to ensure the safety of medications throughout the world.

It is recognised that the EMA and FDA (Agencies) have collaborated on IDMP standards development and systems for a number of years. This Framework further supports and enhances that collaboration through the establishment of governance that focuses on authority, decision-making and accountability with respect to joint IDMP activities.

Background

ISO IDMP suite of standards came from a need to standardise the definition of medicinal product and substance information to facilitate the unique identification and exchange of such information in the context of pharmacovigilance. The IDMP harmonised standards build on the regulatory, scientific, and technical processes already established and support the population and maintenance of existing systems/applications with fully validated, verified and reliable regulatory medicinal product and substance information. The concept may support a variety of regulatory initiatives / use cases, including:

1. Basic research (e.g. substances) and clinical research (study information for "investigational products");
2. Marketing authorisation and post-marketing pharmacovigilance;
3. Regulatory affairs (e.g., product names, regulatory procedures and applications);
4. Manufacturing (e.g., manufacturing methods, partners, certificates), packaging (approved packaged products) and marketing/local affiliates;

EMA-FDA Collaboration Framework Charter



Further supports and enhances the collaboration via a governance focused on decision-making, authority & accountability






EMA-FDA Collaboration Framework Charter




MEDICAL
MEDICINE



- **Joint cooperation with SDOs**
- **Development and maintenance of the ISO standards**
- **GSRS / EU SRS: Scope and Maintenance**
- **Initiate pilots for various to ensure info exchange**
- **Coordinate with other international standardization activities**
- **Focus GSRS / EU SRS on global content & support**

Global IDMP Working Group

- Global Identification of Medicinal Products Working Group (GIDWG) is chartered based on the recommendations from the IDMP Workshop in Geneva hosted by the World Health Organization on 11-12 September 2019.
- Phase 1 of GIDWG will have European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA) and WHO -Uppsala Monitoring Center (UMC) as its chartered members.



Conduct and report on projects leading to the establishment of a framework for the global implementation of the ISO IDMP standards and maintenance of global identifiers.

GLOBAL IDMP WORKING GROUP

Charter

1. INTRODUCTION

This charter establishes the Global Identification of Medicinal Products Working Group (GIDWG). The initial Phase 1 members are European Medicines Agency (EMA), United States Food and Drug Administration (US FDA) and the World Health Organization Collaborating Centre for International Drug Monitoring / Uppsala Monitoring Center (WHO-UMC). The Charter sets the GIDWG's mission, scope, membership, roles and responsibilities, and governance.

This working group was established as a result of the IDMP Workshop hosted by the World Health Organization on 11-12 September 2019 in Geneva. The summary notes of the workshop proposed a set of actions and recommendations that included the formation of a working group to explore and conduct pilot projects focused on the creation and maintenance of global substance and pharmaceutical product IDs (PhPIDs) that would lead to the global implementation of the IDMP standards and further outreach and collaboration with stakeholders.

2. MISSION


The GIDWG will conduct and report on projects leading to the establishment of a framework for the global implementation of the ISO IDMP standards and maintenance of global identifiers.

3. SCOPE

The scope includes:

1. Understand and develop consensus on the issues and mitigation strategies with the ISO IDMP standards, their Technical Specifications and message infrastructure.
2. Develop and prioritize a list of global IDMP implementation use cases.
3. Understand the IDMP implementation status and challenges in each region.
4. Understand and develop a consensus on what is the best pathway to a global substance ID.
5. Articulate and develop consensus on use of UMC as the organization for maintenance of global identifiers, i.e., Substance ID and PhPID.
6. Develop a consensus on best practices, processes, operating model for maintenance of global identifiers for marketed medicinal products.
7. Identify, recommend, and participate in pilot projects.
8. Identify and recommend best approaches for communicating outcomes / summary of findings to other stakeholders.

GIDWG Organization and Governance



Convergence in Cross Region Collaboration




ISO IDMP
1st ISO publication
of the standards.



WHO IDMP
Meeting 2019



ISO IDMP
1st ISO publication
of the standards.



Global IDMP WG


Topics



ISO IDMP Standards



Challenges to Global IDMP Implementation



Cross-Region Collaboration on Global IDMP Implementation



Solutions for Global IDMP Implementation




IDMP Use Cases for Drugs and Biologics

Planned Pilots to Conduct in 2022

1. Global Substance ID


- Scope
 - Mapping EU-SRS EUTCT, FDA UNII, and one additional region (if possible) to Global identifier for a set of selected Chemicals in WHO Model List of Essential Medicines
 - Review all substance classes including more complex scenarios like certain biologics
- Success Criteria
 - Meet requirements for unique substance identification
 - Identify and address issues and challenges
 - Identify and address regional legacy substance definition/identification
 - Propose a feasible, scalable, and most efficient operation model to maintain global substance identifiers (and definition and identification)



Planned Pilots to Conduct in 2022

2. Global Dose Form Identifier

- **Rationale**
 - To ensure consistent mapping to EDQM characteristics for products with less granular dose form expressions
- **Scope**
 - Map DF to another region using the DF characteristic approach
 - Further investigate DF characteristic combination and EDQM DF characteristic with multiple values
- **Success Criteria**
 - Identify and address issues and challenges
 - Documented rules to apply proper DF characteristics, for the generation of global PhPID, regardless regional DF variations



Planned Pilots to Conduct in 2022


• 3. Strength Definitions Identifier

- **Rationale**

- To build on the FDA/ WHO-UMC pilot developed concepts the use of strength presentation versus strength concentration for different products

- **Scope**

- Identify and address different representation of strength for products in different regions
- Work with ISO, clarify the use of presentation strength and concentration strength

Pattern	Type of product
A	
B	
C	
D	

Planned Pilots to Conduct in 2022

• 4. HL7 FHIR for IDMP

Scope

- Participate in the development, verification, and ballot of HL7 FHIR resources related to IDMP

Success Criteria

- Successful exchange of medicinal product and substance information including EU-SRS/SMS, FDA-SRS and UMC-SRS using HL7 FHIR as the underling messaging technology for ISO IDMP standards
- Demonstrate in HL7 FHIR connectathons and other stakeholder events

Dependencies

- ISO 11615 and ISO/TS 20443
- ISO 11238 and ISO/TS 19844

Planned Pilots to Conduct in 2022


- **5. Operating model**

- **Scope**

- Demonstration of the consensus-based operating model for WHO-UMC as the international maintenance organization as an end-to-end pilot

- **Success Criteria**


- Successful process from request to publication of global PhPID for a set of selected cases



IDMP Collaboration Roadmap 2019-2022



MEDICINE@
MEDICINE




Topics



ISO IDMP Standards




Challenges to Global IDMP Implementation



Cross-Region Collaboration on Global IDMP Implementation



Solutions for Global IDMP Implementation



IDMP Use Cases for Drugs and Biologics

IDMP

Points to Consider for Biologics

Vada A. Perkins, MSc, MS

Executive Director, Regulatory Policy & Innovation

Bayer Pharmaceuticals



**Toward Global Identification of Medicinal Products (IDMP)
Implementation**

January 27, 2022

Disclaimer: The views and opinions expressed in these PowerPoint slides are those of the individual presenter and should not be attributed to Bayer, its directors, officers, employees, volunteers, members, chapters, councils, Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries.

Global Substance and Pharmaceutical Identifier Challenge

- In order to have a robust global substance identifier and global pharmaceutical product identifier, the unique and scientific **identification of a substance** must occur.
 - Objective, defining (mandatory) elements to associate and differentiate substances utilized in medicinal products to ensure global harmonization given that regional requirements will still need to be accommodated.

Challenges with ISO Standard for Global PhPID



- PhPID Set
 - ❖ PhPID_Substance Level_L1 → Substance(s) Term
 - ❖ PhPID_Substance Level_L2 → Substance Term(s) +Strength+ reference strength
 - ❖ PhPID_Substance Level_L3 → Substance Term(s) + *Administrable Dose Form*
 - ❖ PhPID_Substance Level_L4 → Substance(s) Term+ Strength + reference strength + *Administrable Dose Form*

- No global agreement on common substance IDs for Global PhPIDs at all levels
- No global consensus on Dose Form Representations for level 3 and level Global PhPIDs
- Dose Form expression variations among regions
- Strength (and units) expression variations among regions

Challenges discovered and relation to ISO Standards for substances (ISO 11238 / TS 19844)



- **Issues:**
 1. Global Substance ID has not been identified by regulatory agencies
 2. Consistent identification of substance will require global maintenance
 3. Can a core set of data fields with non-confidential unambiguously identify a substance?
 4. Harmonized capture of standardized information not always well defined for global Substance and PhPID

Characteristics: Small vs. Large Molecules

Small Molecule Drugs


- Simple, well defined, independent of manufacturing process
- Produced by chemical synthesis
- Predictable chemical process
- Identical copy can be made
- Easy to characterize completely
- Stable
- Mostly non-immunogenic

Biological Drugs

- Complex (heterogeneous), defined by the exact manufacturing process
- Produced in living cell culture
- Difficult to control from starting material to final API
- Impossible to ensure identical copy
- Cannot be characterized completely (e.g., molecular composition and heterogeneity)
- Unstable, sensitive to external conditions

Small Molecule Drug / Pharmaceutical

Aspirin
21 atoms




Large Molecule Drug Human Growth Hormone

~3,000 atoms




Large Biologic Herceptin


~25,000 atoms




Aspirin



2D





3D





Crystal

Tablet Manufacturing




Biologics Manufacturing



Biologics Manufacturing Process



- Traditional drug products usually consist of pure chemical substances that are easily analyzed after manufacture
- Limited ability to identify the identity of the clinically active component(s) of a complex biological product
 - Biologics defined by their manufacturing processes
- Changes in the manufacturing process, equipment or facilities could result in changes in the biological product
 - May require additional clinical studies to demonstrate the product's safety, identity, purity and potency




Source: Rheumatology 2017;56:iv14iv29 doi:10.1093/rheumatology/kex278

IDMP: Substance Groups and Defining Elements

- **Chemicals**

- **Defined primarily by molecular structure** (connectivity and stereochemistry)



- **Proteins**

- **Amino Acid Sequence**, type of **glycosylation**, modifications



- **Nucleic Acids**

- **Sequence**, type of sugar and linkage, modifications

CCTTACTTATAATGCTCATGCTA
GGAAATGAATATTACGAGTACGAT

- **Polymers** (Synthetic or biopolymers)

- Structural repeating units, type, geometry, type of copolymer (block or random), ratio of monomers, modifications, **molecular weight** or properties related to molecular weight, **biological source** for many biopolymers




- **Structurally Diverse Substances** (viruses, cells, tissues, complex materials)

- **Taxonomic, anatomical, fractionation, physical properties, modifications**

Considerations for Unique Substance Identification vs Product Identification

Naming Conventions : **USAN/INN**

- **Acetaminophen** (USAN)/**Paracetamol** (INN)
- **Amoxicillin**: INN-amoxicillin/USAN-amoxicillin
 - Trihydrate (C₁₆H₂₅N₃O₈S)
 - Anhydrous (C₁₆H₁₉N₃O₅S)
- **Amlodipine** (compound, besylate, maleate, mesylate)
 - Amlodipine (C₂₀H₂₅ClN₂O₅)
 - Amlodipine besylate (C₂₆H₃₁ClN₂O₈S)



2.4.1 MeSH Entry Terms

Actimoxi
 Amoxicillin
 Amoxicillin Anhydrous
 Amoxicillin monopotassium salt
 Amoxicillin monosodium salt
 Amoxicillin Sodium
 Amoxicillin trihydrate
 Amoxicillin, (R*)-isomer
 Amoxicilline

Considerations for Unique Substance Identification vs Product Identification

Naming Conventions and Substance/Product Identification for biologics is more complex...



Biologicals
Volume 60, July 2019, Pages 15-23



Review

The INN global nomenclature of biological medicines: A continuous challenge

James S. Robertson ^a, Wai-Keung Chui ^b, Armando A. Genazzani ^c, Sarel F. Malan ^d, Ana López de la Rica Manjavacas ^e, Gilles Mignot ^f, Robin Thorpe ^g, Raffaella Balocco ^g, Menico Rizzi ^c ✉

Show more 

+ Add to Mendeley  Share  Cite


<https://doi.org/10.1016/j.biologicals.2019.05.006> [Get rights and content](#)

Under a Creative Commons [license](#) [open access](#)

Examples: Unique Identification (Biologics)

Vaccines (SARS-CoV-2)

- **Viral vector**
- **Protein-based**
- **Genetic**
 - Genes administered directly as either DNA or RNA
- **mRNA**
 - Pfizer (COVID-19 Vaccine, mRNA)
 - Moderna (COVID-19 Vaccine)




Insulin

- Insulin Aspart
 - Rapid-acting
- Insulin Glargine
 - Long-acting

Influenza

- Egg vs cell-based
- Inactivation method

Example: Coronavirus Vaccines



Unique Identification (Biologics): SARS-CoV-2 (mRNA)



ELASOMERAN

- UNII: EPK39PL4R4
- Preferred Substance Name: ELASOMERAN
- 2430046-03-8
- CX-024414
- ELASOMERAN [INN]
- ELASOMERAN [WHO-DD]
- M-1273

MODERNA COVID-19 VACCINE RNA

- MRNA-1273
- MRNA-BASED VACCINE
- TAK-919

TOZINAMERAN

- UNII: 5085ZFP6SJ
- Preferred Substance Name: TOZINAMERAN
- 2417899-77-3
- BNT162B2
- BNT-162B2
- COMIRNATY

PFIZER COVID-19 VACCINE

- RNA INGREDIENT BNT-162B2
- TOZINAMERAN [INN]
- TOZINAMERAN [WHO-DD]

3. Difference in formulation

Go to:

The three LNP-based drugs share multiple similarities in their formulation, and hence, behave similarly as nanoparticles in vivo. Importantly, all LNPs are composed of four types of lipids; ionizable lipid, phospholipid, cholesterol, and PEG-lipid (Fig. 3). All 3 ionizable lipids have tertiary amine group with pKa 6.0–6.7. These lipids switch its charge from neutral to cationic based on the neutral pH in the blood and the acidic pH in endosomes. The 3 PEG-lipids have dialkyl chains 14-carbon long, which are important for the rapid dissociation from the surface of LNPs once inside the body [43]. The biodegradable design of ALC-0315 [44] and SM-102 [11] is described later.

Active ingredient (Company)	Patisiran (Alnylam)	Tozinameran (Pfizer/BioNTech)	Elasomeran (Moderna)
Ionizable lipid	 Dlin-MC3-DMA	 ALC-0315	 SM-102
Phospholipid	 DSPC		
Sterol	 Cholesterol		
PEG-lipid	 PEG ₂₀₀₀ -C-DMG	 ALC-0159	 PEG ₂₀₀₀ -DMG

[Open in a separate window](#)

Fig. 3

Chemical structure of lipids in lipid nanoparticles. ALC-0159 has PEG₂₀₀₀. All 3 ionizable lipids have tertiary amine groups, namely Dlin-MC3-DMA (MC3), pKa 6.44 [12] or pKa 6.35 [11]; ALC-0315, pKa 6.09 [44]; and SM-102, pKa 6.68 [11]. The related patents are as follows: Dlin-MC3-DMA, WO/2010/144740; ALC-0315, WO/2017/075531 (Lipid No. 3); and SM-102, WO/2017/049245 (Compound 25).

What Now: OBSERVE & ENGAGE!

Health Authority Initiatives

- EMA-FDA Collaboration Framework Charter
- **Global IDMP Working Group (GIDWG)**
- EU SPOR Initiative
- US FDA Roadmap (2022-202x)

Trade Association Engagement


- PhRMA
- EFPIA
- Medicines for Europe, others...

IDMP-Specific Forums



- **IRISS Forum** (non-profit)
 - IDMP Topic Group

UNICOM (EU)

- EU Commission funded initiative for the implementation of ISO IDMP in Europe (and globally).
 - IDMP in a Capsule (infographic)



Topic Groups



Global Substance Registration Public Resources (G-SRS)-FDA/NCATS Collaboration




- Software (open source), data and info on GSRS from NCATS
 - <https://tripod.nih.gov/ginas>
- Global Ingredient Archival System (GInAS)
 - GInAS Notification List
 - <https://tripod.nih.gov/ginas>


G-SRS (FDA) Expert and Point of Contact:
Dr. Lawrence Callahan/Dr. Frank Switzer

Summary

- Distinct points to consider for identifying biologics vs chemical substances
- Different considerations for different types of biologics
 - Global PhPID **will not work** if substances are not uniquely identified on an international scale
 - A global maintenance organization for substances and pharmaceutical product identification is key
- **Manufacturing process(es) is critical to global and unique identification**
- Nomenclature and robust scientific identification is **foundational**
 - Process by which small molecules (i.e., chemicals) are identified is **not sufficient** for large molecule identification
 - INN/USAN (+)



**“The significant problems we
have cannot be solved at the
same level of thinking with
which we created them.”**





Thank You and Acknowledgments

Ron Fitzmartin, PhD, MBA

Ta-Jen Chen

Lawrence Callahan, PhD

Frank Switzer, PhD

Joan Blair

Mary Ann Slack

Toward Global Identification of Medicinal Products (IDMP) Implementation: A Focus on Biologics

Ron Fitzmartin, PhD, MBA
Sr. Informatics Advisor
Office of the Director
Center for Biologics Evaluation and
Research (CBER) | FDA

Ta-Jen Chen
Sr. Project Management Officer
Office of Strategic Programs (OSP)
Center for Drug Evaluation and Research (CDER) |
FDA

Vada Perkins, MSc, MS
Executive Director, Regulatory Policy & Innovation
Bayer Pharmaceuticals

- EFPIA ERAO Working Group
- PhRMA IT Working Group
- ISO TC 215 WG 6 IDMP Co-chair
- ICH M2 EFPIA Topic Lead

Thank You for Attending

CDER Small Business & Industry Assistance (SBIA)
January 27, 2022